Biofilms: A developmental niche for vancomycin-intermediate Staphylococcus aureus

被引:0
|
作者
Chapman, Jenelle E. [1 ]
George, Shilpa E. [2 ]
Wolz, Christiane [2 ]
Olson, Michael E. [1 ,3 ]
机构
[1] Southern Illinois Univ, Dept Med Microbiol Immunol & Cell Biol, Sch Med, Springfield, IL USA
[2] Univ Tubingen, Interfac Inst Microbiol & Infect Med, Tubingen, Germany
[3] 800 N Rutledge St, Springfield, IL 62702 USA
关键词
Staphylococcus aureus; Biofilm; Insurance hypothesis; DNA repair; Vancomycin; COMPLETE GENOME SEQUENCE; SOS RESPONSE; ANTIBIOTIC-RESISTANCE; 2-COMPONENT SYSTEM; GENE; MECHANISMS; PROTEIN; STRAIN; EPIDEMIOLOGY; INFECTIONS;
D O I
10.1016/j.meegid.2023.105545
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Staphylococcus aureus are gram-positive bacteria responsible for a wide array of diseases, ranging from skin and soft tissue infections to more chronic illnesses such as toxic shock syndrome, osteomyelitis, and endocarditis. Vancomycin is currently one of the most effective antibiotics available in treating patients infected with methicillin-resistant S. aureus (MRSA), however the emergence of vancomycin-resistant S. aureus (VRSA), and more commonly vancomycin-intermediate S. aureus (VISA), threaten the future efficacy of vancomycin. Intermediate resistance to vancomycin occurs due to mutations within the loci of Staphylococcal genes involved in cell wall formation such as rpoB, graS, and yycG. We hypothesized the VISA phenotype may also arise as a result of the natural stress occurring within S. aureus biofilms, and that this phenomenon is mediated by the RecA/SOS response. Wildtype and recA null mutant/lexAG94E strains of S. aureus biofilms were established in biofilm microtiter assays or planktonic cultures with or without the addition of sub-inhibitory concentrations of vancomycin (0.063 mg/l - 0.25 mg/L ciprofloxacin, 0.5 mg/l vancomycin). Efficiency of plating techniques were used to quantify the subpopulation of biofilm-derived S. aureus cells that developed vancomycin-intermediate resistance. The results indicated that a greater subpopulation of cells from wildtype biofilms (4.16 x 102 CFUs) emerged from intermediate-resistant concentrations of vancomycin (4 mu g/ml) compared with the planktonic counterpart (1.53 x 101 CFUs). Wildtype biofilms (4.16 x 102 CFUs) also exhibited greater resistance to intermediate-resistant concentrations of vancomycin compared with strains deficient in the recA null mutant (8.15 x 101 CFUs) and lexA genes (8.00 x 101 CFUs). While the VISA phenotype would be an unintended consequence of genetic diversity and potentially gene transfer in the biofilm setting, it demonstrates that mutations occurring within biofilms allow for S. aureus to adapt to new environments, including the presence of widely used antibiotics.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Vancomycin-intermediate resistance in Staphylococcus aureus
    Hiramatsu, Keiichi
    Kayayama, Yuki
    Matsuo, Miki
    Aiba, Yoshifumi
    Saito, Michie
    Hishinuma, Tomomi
    Iwamoto, Akira
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2014, 2 (04) : 213 - 224
  • [2] Vancomycin-intermediate Staphylococcus aureus in Korea
    Kim, MN
    Pai, CH
    Woo, JH
    Ryu, JS
    Hiramatsu, K
    JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (10) : 3879 - 3881
  • [3] The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus
    Appelbaum, PC
    CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 : 16 - 23
  • [4] A Novel δ-Hemolysis Screening Method for Detecting Heteroresistant Vancomycin-Intermediate Staphylococcus aureus and Vancomycin-Intermediate S-aureus
    Cafiso, V.
    Bertuccio, T.
    Spina, D.
    Purrello, S.
    Blandino, G.
    Stefani, Stefania
    JOURNAL OF CLINICAL MICROBIOLOGY, 2012, 50 (05) : 1742 - 1744
  • [5] Septic arthritis caused by vancomycin-intermediate Staphylococcus aureus
    Lu, JJ
    Lee, SY
    Hwa, SY
    Yang, AH
    JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (08) : 4156 - 4158
  • [6] Selection of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus by Imipenem
    Katayama, Yuki
    Murakami-Kuroda, Hiroko
    Cui, Longzhu
    Hiramatsu, Keiichi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (08) : 3190 - 3196
  • [7] Survival of vancomycin-intermediate Staphylococcus aureus on hospital surfaces
    Zarpellon, M. N.
    Gales, A. C.
    Sasaki, A. L.
    Selhorst, G. J.
    Menegucci, T. C.
    Cardoso, C. L.
    Garcia, L. B.
    Tognim, M. C. B.
    JOURNAL OF HOSPITAL INFECTION, 2015, 90 (04) : 347 - 350
  • [8] Synergy of flavone with vancomycin and oxacillin against vancomycin-intermediate Staphylococcus aureus
    Bakar, Nur Salwani
    Zin, Noraziah Mohamad
    Basri, Dayang Fredalina
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 25 (03) : 633 - 638
  • [9] DIFFERENTIAL INFLAMMATORY RESPONSES IN MACROPHAGES BY VANCOMYCIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS AND VANCOMYCIN-INTERMEDIATE STAPHYLOCOCCUS AUREUS
    Lee, H. -S.
    Kuo, T. -Y.
    INFLAMMATION RESEARCH, 2011, 60 : 159 - 159
  • [10] Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore
    Fong, R. K. C.
    Low, J.
    Koh, T. H.
    Kurup, A.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2009, 28 (08) : 983 - 987